Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients

Table 2 Characteristics of patients enrolled and not enrolled in the study

Characteristic		Enrolled (n = 100)	Declined (n = 21)	P-value
Median age in years (range)		5.1 (0.1-17.0)	4.0 (0.1-14.2)	0.73
Female gender		45 (45%)	5 (24%)	0.09
Ethnicity				1^a
	Hispanic	43 (43%)	10 (48%)
	Non-Hispanic	51 (51%)	11 (52%)
	Not reported	6 (6%)	-
Race				0.17^b
	White	56 (56%)	18 (85%)
	Black or African American	12 (12%)	1 (5%)
	Asian	4 (4%)	1 (5%)
	American Indian or Alaska Native	4 (4%)	1 (5%)
	Multiple	6 (6%)	-
	Not reported	18 (18%)	-
Tumor location				0.22
	CNS	33 (33%)	10 (48%)
	Non-CNS	67 (67%)	11 (52%)
Tumor metastatic at diagnosis		34 (34%)	ND
Adjuvant tumor treatment planned		82 (82%)	ND
Tumor available for WES		84 (84%)	14 (67%)	0.12
Interpreter and Spanish consent form used		15 (15%)	4 (19%)	0.74
Median days from surgery to study decision (range)		36 (5-63)	42 (20-61)	0.052

^aP-value was calculated with ‘Not reported’ subjects excluded. ^bComparison was made between ‘White’ versus others with ‘Not reported’ subjects excluded. Two sample rank sum tests were used to compare the continuous data and Fisher’s exact tests were used for the categorical data. CNS, central nervous system; ND, not determined; WES, whole exome sequencing.

ISSN: 1756-994X